Invitro Diagnostics Market Forecasts to 2030 – Global Analysis By Product and Service (Reagents & Kits, Instruments, Services and Data Management Software), Technology (Immunoassay/ Immunochemistry, Hematology, Microbiology, Urinalysis, Clinical Chemistry

Invitro Diagnostics Market Forecasts to 2030 – Global Analysis By Product and Service (Reagents & Kits, Instruments, Services and Data Management Software), Technology (Immunoassay/ Immunochemistry, Hematology, Microbiology, Urinalysis, Clinical Chemistry, Molecular Diagnostics, Coagulation and Hemostasis and Other Technologies), Application, End User and By Geography.

According to Stratistics MRC, the Global In vitro Diagnostics Market is accounted for $98.14 billion in 2023 and is expected to reach $148.54 billion by 2030 growing at a CAGR of 6.1% during the forecast period. In vitro diagnostics (IVD) refers to a category of medical tests and diagnostic techniques on biological samples such as blood, urine, and tissues. These tests are used to monitor and identify autoimmune diseases, infectious diseases, and a variety of other medical conditions. They may also be used to analyse changes in drug therapy. Moreover, they enable precise and timely diagnoses, contributing to improved health outcomes, reduced healthcare costs, and the prevention of disease spread.

According to the International Diabetes Federation (IDF), in 2021, there were 537 million people across the globe suffering from diabetes, and the number is expected to increase to 643 million by 2030.

Market Dynamics:

Driver:

Increasing awareness of early disease diagnosis in emerging economies

The growing awareness of early disease diagnosis in emerging economies stands out as a significant driver of the in vitro diagnostics (IVD) market. As healthcare awareness and education improve in these regions, more people are seeking preventive healthcare measures and early disease detection. Early diagnosis often results in better treatment outcomes, reduced healthcare costs, and improved overall health. This awareness not only benefits individuals but also prompts healthcare systems and governments to invest in diagnostic infrastructure, thus boosting the demand for IVD products and services. Moreover, as emerging economies expand their healthcare access, there is a greater need for cost-effective and accessible diagnostic solutions, driving innovation and market growth in the IVD sector to meet these demands.

Restraint:

High cost

The expenses associated with developing, producing, and procuring IVD tests and equipment can be substantial. These costs are often passed on to healthcare providers and patients, leading to affordability challenges. Inadequate reimbursement and limited healthcare budgets further exacerbate the financial burden. This can result in reduced access to essential diagnostic services, particularly in resource-constrained settings, hindering early disease detection and management. Therefore, this will hamper market demand.

Opportunity:

Technological advancements

Continuous innovation in diagnostic technologies is revolutionising healthcare by enhancing accuracy, efficiency, and accessibility. Advanced techniques, such as molecular diagnostics, lab-on-a-chip platforms, and next-generation sequencing, allow for quicker and more precise test results. The development of portable and point-of-care testing devices makes diagnostics more convenient, especially in remote or resource-limited areas. Additionally, the integration of IVD with digital health platforms and artificial intelligence further enhances data analysis and interpretation. These advancements not only improve patient care but also reduce healthcare costs. IVD companies that invest in research and development to leverage these technologies can gain a competitive edge and tap into the expanding market for cutting-edge diagnostic solutions

Threat:

Stringent regulations and legal standards

Stringent regulatory and legal guidelines pose a significant threat to the in vitro diagnostics (IVD) market. These guidelines often imposed to ensure the safety and efficacy of diagnostic tests, can lead to increased compliance costs, lengthy approval processes, and market entry barriers for IVD manufacturers. Non-compliance can result in fines and product recalls. Additionally, evolving regulations can make it challenging for companies to keep up with changing standards, impacting product development and innovation.

Covid-19 Impact

During the COVID-19 pandemic, several segments witnessed both positive and negative effects. The market experienced a positive impact due to the increased use of molecular diagnostics, which counteracted the negative effects of other categories. Furthermore, among hospitalised COVID-19 patients, there was a rise in the need for test kits and consumables for monitoring blood glucose and troponin levels. Participants have experienced a significant increase in sales of molecular and point-of-care tests, which has resulted in a significant increase in their earnings. However, a significant drop in routine testing carried out in hospitals and laboratories globally caused some major firms to see a dip in their revenue margins.

The Diabetes segment is expected to be the largest during the forecast period

The Diabetes segment is estimated to hold the largest share. Diabetes, a chronic metabolic disorder, represents a significant segment of the in vitro diagnostics (IVD) market. Diagnostic tests for diabetes are vital for the early detection, monitoring, and management of the condition. The IVD market for diabetes includes blood glucose monitoring devices, HbA1c tests, and various other assays for assessing blood sugar levels. As the global prevalence of diabetes continues to rise, this segment experiences consistent growth. Furthermore, IVD innovations play a crucial role in delivering precise and convenient tools for both patients and healthcare professionals to effectively control diabetes, reduce complications, and enhance the quality of life for millions of individuals affected by the disease.

The Clinical Laboratories segment is expected to have the highest CAGR during the forecast period

The Clinical Laboratories segment is anticipated to have lucrative growth during the forecast period. Clinical laboratories are a fundamental segment of the in vitro diagnostics (IVD) market. These specialised facilities conduct various diagnostic tests on patient samples, such as blood, urine, and tissue, to aid in disease diagnosis, treatment, and monitoring. They play a crucial role in healthcare, providing essential information to healthcare providers for decision-making. Moreover, clinical laboratories offer a wide range of tests, including chemistry, microbiology, haematology, immunology, and molecular diagnostics. The clinical laboratory industry is growing due to the growing need for accurate and timely patient care as well as the need for healthcare services.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The Asia-Pacific region represents a rapidly growing and dynamic sector within the global in vitro diagnostics (IVD) market. With diverse and populous countries, such as China, India, and Japan, this region is witnessing significant expansion in healthcare infrastructure and increasing healthcare expenditures. Factors contributing to the growth include rising disease prevalence, increasing awareness of early disease detection, and growing access to healthcare services. Moreover, government initiatives and regulatory reforms are driving quality and accessibility in diagnostic testing. The COVID-19 pandemic has also emphasised the importance of IVD in the region, with a surge in demand for testing.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, owing to the well-established healthcare industry and the rising prevalence of chronic diseases. The region is characterised by a competitive landscape with prominent companies like Abbott Laboratories, Thermo Fisher Scientific, and Roche Diagnostics. Moreover, the market benefits from a strong focus on research and development, leading to the introduction of cutting-edge diagnostic tests and technologies. Regulatory bodies, such as the FDA in the United States, ensure quality and safety standards. Additionally, the COVID-19 pandemic has underscored the importance of IVD tests in the region for diagnosing, tracking, and managing infectious diseases.

Key players in the market

Some of the key players in the In vitro Diagnostics Market include Freenome Holdings, Inc., Agilent Technologies, Inc., Natera, Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Sysmex Corporation, Siemens Healthineers AG, BD (Becton, Dickinson, and Company), Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., Alere, Inc., InterVenn Biosciences, Guardant Health, Thermo Fisher Scientific, Inc., NeoGenomics Laboratories, Invitae Corporation, Beckman Coulter, Danaher and Illumina, Inc.

Key Developments:

In May 2023, Freenome, a privately held biotech company, announced that it has acquired Oncimmune Ltd, a UK-based global immunodiagnostics developer with a commercialized CE-IVD marked EarlyCDT Lung blood test, autoantibody platform and research and development pipeline of 7+ cancer detection signatures.

In November 2022, Thermo Fisher Scientific (US) launched the rapid RT-PCR Accula Flu A/Flu B Test designed to enable healthcare providers to detect and differentiate influenza A and B in about 30 minutes.

In October 2022, Thermo Fisher Scientific (US) entered a definitive agreement to acquire The Binding Site Group, a global leader in specialty diagnostics. The Binding Site provides specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders.

In September 2022, Sysmex Corporation (Japan) launched the UF-1500 Fully Automated Urine Particle Analyzer (UF-1500) for urine sediment testing. The UF-1500 inherits the high levels of functionality and usability of the UF-5000 Fully Automated Urine Particle Analyzer (UF-5000).

In August 2022, Al-Futtaim Health (Dubai) and Abbott Laboratories (US) entered into a strategic partnership to improve the standards of advanced laboratory diagnostics in Dubai.

Product and Services Covered:
• Reagents & Kits
• Instruments
• Services
• Data Management Software

Technologies Covered:
• Immunoassay/ Immunochemistry
• Hematology
• Microbiology
• Urinalysis
• Clinical Chemistry
• Molecular Diagnostics
• Coagulation and Hemostasis
• Other Technologies

Applications Covered:
• Infectious Diseases
• Drug Testing/ Pharmacogenomics
• Oncology
• HIV/AIDS
• Diabetes
• Autoimmune Diseases
• Cardiology
• Nephrology
• Other Applications

End Users Covered:
• Hospital Laboratories
• Academic Institutes
• Patients
• Point-of-Care Testing Centers
• Clinical Laboratories
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances